• Publication & Reference: Phase ll, open-label, randomized, multi-centre trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol. 2018;36:951-958
  • DOI: 10.1200/JCO.2017.76.0611
  • Author(s): Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G.
Research Theme | MRI

Publication & Reference

Phase ll, open-label, randomized, multi-centre trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol. 2018;36:951-958

DOI

10.1200/JCO.2017.76.0611

Author(s)

Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G.
Back to all publications

Contact Us

NIHR Biomedical Research Centre: Nottingham
Research & Innovation
D Floor (via South Block)
Nottingham University Hospitals NHS Trust
Queen’s Medical Centre
Derby Road
Nottingham
NG7 2UH

Telephone: 0115 924 9924

Director: Professor Ian Hall

Hosted by

Nottingham University Hospitals Logo

Nottingham University Hospitals Logo

We are a partnership between Nottingham University Hospitals NHS Trust and the University of Nottingham, supported by NHS and academic partners in Nottingham and across the East Midlands.

Website by Volute